ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1499

Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease with Rheumatoid Arthritis

Masaomi Yamasaki, Rheumatology, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Anti-CCP antibodies and interstitial lung disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Serum anti-cyclic citrullinated peptide antibodies (anti-CCP2) positivity was associated with presence of interstitial lung disease and airway disease in rheumatoid arthritis (RA). This study analyze whether high resolutional CT (HRCT) and anti-CCP2 can predict the outcome of ILD in RA.

Methods: 472(Male74/Female398, age 58.9+/-14.0) cases were analyzed in this study. Participants met 2010 ACR/EULAR classification criteria of RA were followed up at least one year as newly onset RA. All patients were also performed chest radiological examinations at the initial presentation. ILD extension Score was determined based on the presence and extent of ILD features (i.e., ground glass opacification (GGO), reticulation and honeycombing (HC) using a semiquantitative scale at the each of the three zones of each lung with a maximum total score possible of 6. HRCT parameters which include ILD extension Score and titer of anti-CCP2 at the initial presentation were retrospectively analyzed.

Results: 231 out of 472 patients (48.9%) had abnormal chest radiological findings which included bronchiectasis, bronchitis and ILD. 101 out of 472 patients (21.4%) showed ILD at initial presentation. The titer of anti-CCP2 showed statistical difference between RA only vs. RA-ILD patients( Ave. 47.8 and 164.3 U/ml, respectively, p<0.001). 6 out of 101 RA-ILD patients showed rapidly progressive ILD. These 6 patients had widely spread honeycombing compared to asymptomatic RA-ILD patients (p=0.0012). In 101 RA-ILD patients, higher anti-CCP2 levels were associated with more severe RA-ILD. Average titer of anti-CCP2 in ILD extension Score 1, 2, 3, 4, 6 showed 20.3+/-28.4, 155.0+/-49.6, 290.9+/-26.3, 693.7+/-308.9 and 1582.5+/-120.9 U/ml respectively. Higher extension score of each ILD features GGO (p=0.0052), reticulation (p=0.0047) and honeycombing (p=0.0025) also showed association with higher anti-CCP2.

Conclusion: Anti-CCP2 antibodies are marker of severity and extent of RA-ILD in HRCT. HRCT findings focused on ILD extension Score at the initial presentation is a useful predictor of the outcome of ILD in RA. Anti-CCP2 is one of the related factor of ILD extension Score.


Disclosure: M. Yamasaki, None;

To cite this abstract in AMA style:

Yamasaki M. Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/anti-cyclic-citrullinated-peptide-antibodies-and-severity-of-interstitial-lung-disease-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-cyclic-citrullinated-peptide-antibodies-and-severity-of-interstitial-lung-disease-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology